James Buckley Non-Executive Chairman - Remuneration & Audit Committee Member

James has over fifteen years of experience working with healthcare companies. James’ focus is on companies with very significant growth potential either organically or through acquisition.
Previously he was CEO of Tunstall Healthcare, a world leading provider of
tele-healthcare solutions, growing sales to £150m from 2.5m customers in 30 countries and 1,200 staff globally. James has extensive experience of working in the UK social healthcare market and internationally.

Previously James worked for Cable & Wireless for over ten years, as well as other technology businesses.

Stefano Ciampolini Chief Executive Officer and Co-Founder
 

Stefano Ciampolini is Adjunct Professor of Imperial College Business School in London and Entrepreneur in Residence at Imperial Enterprise Lab as well as a coach at the ETH Innovation & Entrepreneurship Lab in Zurich.

Stefano is a healthcare entrepreneur and the CEO and founder of Renal Services, a UK dialysis services company. He is also managing partner and founder of Healthcare Capital Partners (London), a private equity and corporate finance advisory boutique specialising in life sciences and healthcare ventures and a managing partner and founder at MedScience Ventures (Boston), a life sciences venture capital fund.

As part of his activities Stefano is a founder, board member and investor in several healthcare and medtech ventures and private equity funds focusing on healthcare investments in Europe and the US. He is founder and board member of Pure Life Renal, a US dialysis services company, a founder and board member of biofficient.com, a bio-procurement platform, a founder and board member of UV Light Care, a US medical devices company.

Stefano earned an MBA from Imperial College Business School in London in 1994 and holds a degree in economics from Kingston University in London.

Dr Patrick Carr Head of Medical Advisory Board
 

Dr Carr graduated in medicine from Westminster Hospital Medical School in 1984 and has been a consultant nephrologist since 1995. He is Regional Specialty Advisor in Renal Medicine for the Royal College of Physicians and has been involved in and chaired Specialty Training Committees.

He is vice-chairman of the national Specialty Advisory Committee in Renal Medicine and has special responsibility for Certification and Accreditation. He is also lead for CESR assessments to approve training of non UK trainees so that they may apply to the GMC for specialist certification.
He is a trained Clinical Safety Officer.

Over the past 24 years Dr Carr has held various clinical and management positions mostly focussed on training, information management and safety. He has published in various journals.

Scott Maguire Director and Co-Founder - Remuneration Committee Member

Mr Maguire has over 30 years of global life sciences and healthcare investment banking, management and board experience, raising well in excess of $1billion as an executive and an advisor. Mr Maguire has set up three companies and two divisions of large cap companies.  Having recently been Chairman and CEO of Xenetic Biosciences Inc (XBIO), Scott turned a life science start up with a few patents into a clinical stage company listed on NASDAQ, a listing he led in 2016. He is also co-founder and board member of Renal Services UK Ltd, one of largest providers of dialysis services in the UK. In 2001 he founded Healthcare Capital Partners Ltd, a healthcare and life science corporate finance and proprietary investment boutique which has been responsible for hundreds of millions in investments and exits since its founding. In 1996 he co-founded the Arthur Andersen global healthcare corporate finance practice based in London which he assisted in building from 2 to 35 bankers globally. Scott started his banking career on Wall Street with Merrill Lynch in 1987.

George Tsangarides Remuneration & Audit Committee Member
 

George was appointed to the board at Renal Services as part of the investment from BGF. He sits on the remuneration and audit committees.

George joined BGF in early 2012 and is based in the London office. Covering London, Essex and Norfolk, George is responsible for identifying and completing new investment opportunities as well as continuing to work with the boards of BGF’s investee companies.
Prior to BGF, George advised a number of large cap companies in fundraising and M&A across the Telecoms, Media and Technology sectors as an investment banker at Bank of America Merrill Lynch.
He holds a MA Oxon in Politics, Philosophy and Economics from Oxford University and a MSc in Finance from the London School of Economics.

Henrik Westling Director - Audit Committee Member
 

Henrik graduated from Delta State University, Mississippi and Linkoping University in Sweden with BAs in Finance, Accounting and Management Control. Henrik started his professional career at Arthur Andersen in 1994, where he mainly worked in the Corporate Finance practice in London and in Stockholm. In 2002, he joined Evli Bank in Stockholm following its acquisition of Arthur Andersen’s Nordic Corporate Finance operations. Since then he has been responsible for Evli’s Healthcare Corporate Finance team with focus on healthcare M&A in Northern Europe. Henrik has project led a significant number of domestic and cross-border transactions in the healthcare industry, including several dialysis related transactions.

Yiannos Mouzouris Director
 

Yiannos graduated with a PhD in electrical engineering and MS in finance, investment and banking from the University of Wisconsin-Madison in 1998.

After graduation he worked for Prudential Securities Inc. in New York where he was responsible for structuring asset-backed securities, and subsequently for Tufton Oceanic in Cyprus and Dubai where he was responsible for developing fund management products and working on corporate finance transactions in the maritime sector.

He joined the Interorient Group, Cyprus, in 2005 where he is responsible for business development. He has been actively involved in several acquisitions and joint venture investments and has served on the boards of public and private companies.